ResMetrix

Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15}
Company Profile
Home / Ambulatory monitoring platform that can easily and precisely monitor the lung function, alert the medical provider on deterioration and allow change of treatment at home before Asthma exacerbation. Non invasive accurate monitoring of breathing Recognition of pathologic breathing patterns Breakthrough in Respiratory Care • Novel respiratory disease management technology • Enables non invasive accurate monitoring of breathing • Precise recognition of pathologic breathing patterns • The 4 P’s: Predictive, Personalized, Preemptive, Participatory
Lior Teitelbaum
Lior Teitelbaum
VP Business Development 
Conference attendance
Biography

Mr. Lior Teitelbaum, VP Business Development at MindUP is a healthcare executive with extensive experience in Business Development, Strategy, Scouting and Licensing, Partnering, Portfolio Planning and Strategy and Strategic Alliance Management in the Medical Technology, Pharmaceutical and Biotechnology industries. Prior to joining MindUP Lior was Senior Director of Business Development at BioLineRx LTD, a biopharmaceutical development company, prior to that he served as Director of Business Development at MetaCure, a medical device company focusing on treatment of type 2 diabetes, Prior to that he served as Deal flow and Business Development Manager at Elron Electronic Industries, a technology focused investment company. Lior holds an MBA from the Recanati School of management at Tel Aviv University and an MSc. in molecular genetics from the Weizmann Institute of Science.   

Techsomed

Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15}
Company Website
http://www.techsomed.com/
Company Profile

TechsoMed is an Israeli based medical device company, developing BioTrace™, a real-time, monitoring and control system for thermal ablation procedures. The technology is applicable to multiple fields such as Oncology (tumor ablation), Cardiac (arrhythmia) and Pain management. Our breakthrough technology (based on two granted patents) is the only one which can give physicians real time monitoring and control for ablation procedures, and it can do all that by interfacing with standard ultrasound devices. The control and security we can give physicians will make our system a must-have for major ablation treatments.

Company Type
Pipeline Product 1: Name/Stage
BioTrace - IO
Product 1: Description
BioTrace™  - Transforming the way Thermal ablations are done  BioTrace – IO  World’s first real time monitoring and control system for thermal ablation procedures such as solid tumors. Interfacing with standard ultrasound devices that can be found in almost every clinic / hospital around the world.  Does not change the way the ablation procedure is done, allowing for fast regulatory approval.  Closed loop treatments with continuous feedback to measure therapy outcomes and to achieve the desired results. successfully advanced through proof of concept , working prototype and clinical trials – 37 successful humans cases. 
Yossi Abu
Yossi Abu
LinkedIn logo TechsoMed CEO 
Conference attendance

Virility Medical

Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15}
Company Website
www.virilitymedical.com
Company Profile

Virility Medical is a clinical stage venture, engaged in the development and commercialization of treatment for premature ejaculation by method of neuromodulation. Virility’s product is an intimate perineal skin patch. The patch carries an electronic module that delivers transcutaneous neuromuscular electrical stimulation to the adjacent nerves and muscles. Thus, the muscles are electrically inhibited and, the premature initiation of the ejaculation phase is delayed for the duration of stimulation, after which the patch is disposed of.

Company Type
Keywords

Sex Medicine

Neuromodulation

Premature Ejaculation

Electrical Stimulation

Year Founded
2016
Pipeline Product 1: Name/Stage
vPatch
Mr Tal Gollan
CEO 
Conference attendance